GLOBUS MEDICAL INC
NYSE: GMED·Audubon, Pennsylvania·CIK 0001237831
- Price
- $70.50
- Base IV
- $53.41
Valuation snapshot
At $70.50, the price sits between our base case ($53.41) and bull case ($72.43).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $53.41
- 76% of the price · range $34.52–$72.43
- Price vs base case
- 32% above
- $70.50 against $53.41
- Base case · our researched forecast, 2026-11-15See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $34.52 to bull $72.43. Values per share.
Price against each value
- Bear case
- $34.52
- Price 104% above
- No growth
- …
- —
- Base case
- $53.41
- Price 32% above
What does Globus Medical do?
Globus Medical develops and sells medical devices and technologies to help surgeons treat patients with musculoskeletal disorders.
It brought in $3.1B of sales in the 12 months to Sep 2026.
Led by Keith W. Pfeil, President and Chief Executive Officer since 2025. Globus Medical, Inc. Current Report on Form 8-K (Item 5.02)
- Industry
- Healthcare
- Based in
- Audubon, Pennsylvania
- Trades on
- NYSE as GMED
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 18¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 38¢ of every dollar.
- Making what it sells31¢
- Research and development5¢
- Sales, marketing and admin38¢
- Everything else it takes to operate5¢
- Tax5¢
- Left as profit18¢
- Interest and other income came back in+1¢
Who pays Globus Medical, and for what?
Globus Medical designs and sells medical devices and surgical tools used to treat spine, orthopedic, and chronic pain conditions. It earns revenue primarily by selling spinal implants, biologics, and orthopedic hardware used during surgeries. It also sells and leases robotic guidance, navigation, and imaging systems that assist surgeons during operations.
Hospitals, ambulatory surgery centers, and healthcare systems purchase or lease the company's devices and equipment for use by surgeons.
Musculoskeletal Solutions
95%Implantable devices, biologics, surgical instruments, spinal cord stimulation devices, and neuromonitoring services used in spine and orthopedic procedures.
Precice intramedullary limb lengthening system and external remote controllerImage: Globus Medical, Inc. Enabling Technologies
5%Advanced computer-assisted surgical systems, including robotic navigation, intraoperative imaging, and surgical planning software.
ExcelsiusGPS surgical navigation system in an operating roomImage: Globus Medical, Inc.
Where its work physically happens, beyond headquarters:
- Eagleville Implant Manufacturing — Eagleville, United States. The FY2025 10-K names it as one of the main plants making Globus's spine and orthopedic implants, the bulk of company revenue, so its capacity sets how much of that output Globus makes in-house.
- Methuen Excelsius Robotics Assembly — Methuen, United States. This is where Globus assembles its Excelsius surgical robots, which help pull through sales of its implants, so the site's output limits how fast the robot base can grow.
- Limerick Implant Manufacturing — Limerick, United States. The 10-K names this second Pennsylvania plant as an implant manufacturing site, adding capacity and backup supply for the core musculoskeletal implant business.
- West Carrollton Implant Manufacturing — West Carrollton, United States. The 10-K names it as an implant manufacturing site outside Pennsylvania, part of the owned plant network that supports the implant product line built up through the NuVasive merger.
- Costa Rica Spinal Cord Stimulation Plant (Nevro) — Alajuela, Costa Rica. The 10-K says Globus makes its spinal cord stimulation products in Costa Rica; the plant came with the Nevro acquisition, so it supplies the newly added neuromodulation revenue.
Globus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025
How is the business doing?
Sales grew from $789M in 2020 to $2.9B in 2025, about 30% a year.
Running the business leaves about 22¢ of each sales dollar as operating profit, up from 14¢ in 2020.
After paying for its upkeep and new investment, it had $766.6M of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Globus Medical exists to improve the quality of life for patients suffering from musculoskeletal disorders.
“to improve the quality of life of patients with musculoskeletal disorders”
Who is responsible for the plan?
- Keith W. PfeilPresident and Chief Executive Officer
Keith W. Pfeil oversees the overall strategic direction, operations, and executive leadership of Globus Medical. Globus Medical designs, develops, and commercializes musculoskeletal healthcare solutions and enabling technologies to generate commercial revenue.
- Kyle R. KlineSenior Vice President and Chief Financial Officer
Kyle R. Kline oversees Globus Medical's global finance, accounting, and financial reporting functions as principal financial and accounting officer. Management of financial reporting, capital allocation, and budgeting directly supports commercialization and distribution of the company's musculoskeletal solutions.
Roles checked November 6, 2026.
What management says it is working on now:
Leverage Product Development Engine
Management focuses on rapidly designing and commercializing new products by collaborating closely with surgeons and utilizing comprehensive in-house research and testing facilities.
Globus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025Expand the U.S. Sales Force
Management is focused on expanding the size, geographic scope, and productivity of its exclusive direct and distributor sales network across the United States to deepen market penetration.
Globus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025Accelerate International Growth
The company aims to increase its global footprint beyond the 64 non-U.S. countries it serves by commercializing additional products and adding sales representatives.
Globus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025Pursue Strategic Acquisitions
Management regularly evaluates and pursues complementary acquisitions, such as NuVasive and Nevro, to expand its product portfolio, commercial reach, and technological capabilities.
Globus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025Integrate Enabling Technologies with Implants
The company is focused on increasing hospital adoption of robotic navigation and imaging platforms to drive greater pull-through usage of its proprietary musculoskeletal implants.
Globus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025
- Full-Year 2026 Net Sales, Full Year 2026
- $3.18 billion to $3.22 billion
- Globus Medical Reports Second Quarter 2026 Financial Results
- Non-GAAP Diluted Earnings Per Share, Full Year 2026
- $4.95 to $5.05
- Globus Medical Reports Second Quarter 2026 Financial Results
- Adjusted Gross Profit Margin, Over time
- Mid-70s percentage
- Globus Medical Reports Second Quarter 2026 Financial Results
What's changing right now?
Growth is slowing. In Q3 2026 it sold 1% less than a year earlier. The year before, quarters averaged 20%.
Its operating margin is wider than a year ago: 23¢ per sales dollar, against 18¢.
Since Nov 2026 the share price has fallen 11%, from $79.47 to $70.50.
Recently
November 5, 2026
GAAP operating margin, quarterly changed to 23.3%
GMED Q3 2026 8-KNovember 5, 2026
Total revenue growth, quarterly YoY changed to -0.7%
GMED Q3 2026 8-KSeptember 30, 2026
Revenue YoY Growth Rate, Quarterly changed to -0.7%
Globus Medical Reports Third Quarter 2026 Results
Coming up
November 5, 2026
Third Quarter 2026 Financial Results
Globus Medical will report its third quarter 2026 earnings, providing investors with updated performance figures and full-year guidance revisions.
Globus Medical to Announce Third Quarter 2026 Financial ResultsLate 2026 through 2027
European Commercialization of Excelsius3D
Following CE Mark approval in September 2026, Globus is rolling out its Excelsius3D imaging platform across the European Union and the United Kingdom.
Globus Medical Secures CE Mark for Excelsius3D Imaging SystemLate 2026 through 2027
Commercial Rollout of SCRIPT Patient-Specific Implants
Following recent FDA clearances, the company is commercially launching its SCRIPT patient-specific spinal implants integrated with Excelsius navigation.
Globus Medical Showcases SCRIPT System at NASS 2026December 2027
European Union Medical Device Regulation Compliance Deadline
Medical devices previously marketed under older European directives must transition to full compliance under EU MDR rules to maintain market access.
Globus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025
Our own estimate moved too: the base case went from $66.01 to $53.41 a share between our last two valuations. The biggest reason: Total revenue growth, quarterly YoY moved from an unreported prior value to -0.7%, as reported in GMED Q3 2026 8-K.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Surgeon Adoption and Hospital Purchasing Decisions
The company must convince surgeons and hospitals that its products are attractive alternatives to competitors. Hesitation to adopt new techniques or lack of training could reduce sales.
From the company's own filingsWould hit how fast sales growGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025
Third-Party Reimbursement and Pricing Pressure
Reductions or denials of insurance coverage by Medicare, Medicaid, or private payers could limit patient access to procedures and force price reductions, lowering profit margins.
From the company's own filingsWould hit how much of each sale it keepsGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025
Dependence on Specialized Third-Party Suppliers
Globus relies on a small number of suppliers for finished goods, raw materials, and donor tissue. Any disruption or loss of key suppliers could cause product shortages and lost revenue.
From the company's own filingsWould hit how fast sales growGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025
Competition from Large Medical Device Companies
Major competitors have substantially larger financial, marketing, and distribution resources, and can leverage existing hospital relationships or aggressive pricing to capture market share.
From the company's own filingsWould hit how fast sales growGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025
Open FDA Warning Letter for ExcelsiusGPS
An FDA warning letter regarding complaint handling and medical device reporting for ExcelsiusGPS remains open. Failure to satisfy FDA requirements could trigger fines, recalls, or sanctions.
From the company's own filingsWould hit how much of each sale it keepsGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025
Integration Complexity of Large Acquisitions
Integrating major acquisitions like NuVasive and Nevro involves operational risks. Failure to achieve anticipated cost synergies or sales force retention could hurt profitability.
From the company's own filingsWould hit how much of each sale it keepsGlobus Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025
The revised guidance implies Q4 2026 revenue below Q4 2025, and Nevro is still declining.
From our researchWould hit how fast sales growYahoo Finance Q3 2026 call highlights
Management cut its revenue outlook while holding EPS guidance, which suggests cost cutting is carrying earnings and may not repeat.
From our researchWould hit how much of each sale it keepsGMED Q3 2026 8-K
Is it a good business?
From 2023 to 2025 it earned between 3% and 10% on the capital invested in it, a median of 4%. Its cost of capital in the latest valuation is 9.5%; returns were above it in 1 of the 3 years.
From 2016 to 2025 it earned between 2% and 13% on its shareholders' equity, a median of 11%.
Over 10 years its operating margin ranged from 7¢ to 27¢ per sales dollar, a median of 20¢. Gross margin ran from 59¢ to 78¢.
Cost of capital 9.5%
The number of shares has held roughly steady over the past year.
It holds $516.8M more in cash than it owes.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $70.50. Our put its value between $34.52 and $72.43, with $53.41 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $34.52
Sales were flat to slightly down this past year as the Nevro pain-device business shrank, and this scenario assumes that weakness continues, the core spine business grows slowly, and profits stay around today's level.
Base case, $53.41
After years of fast, deal-driven growth, sales have levelled off, and this scenario assumes they return to steady mid-single-digit growth once the shrinking Nevro business stabilizes, with profits holding near their recent improved level.
Bull case, $72.43
This scenario assumes the recent sales stall is temporary: delayed new products launch, the surgical-robot business keeps growing quickly, and the company returns to the solid growth and rising profits it showed before its big acquisitions.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 32%
For Globus Medical to be worth today's $70.50, sales would need to grow about 11.0% a year. We assume 4.0%. Over the last 5 years, sales grew 27.2% a year.
Or, if sales grow 4.0% as we assume, the price works with a profit margin of 31.6% (we assume 23.5%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 11.0% a year?
Try your own numbersWe're moderately sure of this range: it scores 63 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $53.41 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.0%
- Operating margin23.5%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$53.41 -24.2%

